Travere Therapeutics, Inc. (TVTX)
49.60
-3.19
(-6.04%)
USD |
NASDAQ |
Oct 16, 16:00
49.62
+0.02
(+0.04%)
After-Hours: 20:00
Travere Therapeutics Research and Development Expense (Annual) : 206.01M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 206.01M |
| December 31, 2024 | 217.50M |
| December 31, 2023 | 237.73M |
| December 31, 2022 | 221.07M |
| December 31, 2021 | 208.85M |
| December 31, 2020 | 130.61M |
| December 31, 2019 | 139.80M |
| December 31, 2018 | 122.78M |
| December 31, 2017 | 77.84M |
| Date | Value |
|---|---|
| December 31, 2016 | 70.52M |
| December 31, 2015 | 49.73M |
| December 31, 2014 | 46.70M |
| December 31, 2013 | 7.084M |
| December 31, 2012 | 0.00 |
| February 28, 2011 | 0.00 |
| February 28, 2010 | 0.00 |
| February 28, 2009 | 0.00 |
| February 29, 2008 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| TG Therapeutics, Inc. | 160.22M |
| BioMarin Pharmaceutical, Inc. | 700.97M |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Viridian Therapeutics, Inc. | 338.47M |
| Krystal Biotech, Inc. | 52.32M |